Interferon alfacon-1

Drug Profile

Interferon alfacon-1

Alternative Names: Advaferon; CIFN; IFN-consensus; Infarex; Infergen; Interferon consensus; Interferon-alpha con1; Interferon-alpha consensus; rConINF; Recombinant consensus interferon; Recombinant methionyl interferon consensus; YM 643

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Astellas Pharma; Three Rivers Pharmaceuticals
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C
  • Discontinued Cancer; Coronavirus infections; Non-Hodgkin's lymphoma; Ovarian cancer

Most Recent Events

  • 25 Oct 2010 Three Rivers Pharmaceuticals has been acquired by Kadmon Pharmaceuticals
  • 07 Jul 2010 Registered for retreatment of Hepatitis C in combination with ribavirin in USA (SC)
  • 16 Jun 2009 Final efficacy data from the DIRECT trial in Hepatitis C released by Three Rivers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top